Cosmo Pharmaceuticals N.V. (0RGI.L)
- EQS Group
Cosmo announces acceptance of NDA submission of Cortiment® MMX® in Japan
Cosmo Pharmaceuticals N.V. / Key word(s): Miscellaneous28-Jun-2022 / 06:00 GMT/BSTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Dublin, Ireland – 28 June 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced that Ferring, our partner for Cortiment® MMX® (budesonide), submitted the NDA for Japan on June 23, 2022, and the application has been accepted by PMDA (Pharmaceuticals and Medical Devices
- EQS Group
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
Cosmo Pharmaceuticals N.V. / Key word(s): AGMEGMCosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA 27.05.2022 / 15:15 Press Release (PDF)Dublin, Ireland – 27 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced that its shareholders approved all agenda items at today's virtual annual general meeting of shareholders.8,315,019 ordinary shares in the share capital of Cosmo were represented at thi
- EQS Group
COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
Cosmo Pharmaceuticals N.V. / Key word(s): MiscellaneousCOSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA 03.05.2022 / 06:00 Press Release (PDF)Dublin, Ireland - 3 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announces the expansion of the agreement with Medtronic for the distribution of Eleview(R) to all countries except Canada, following the mutual termination of the license agreement with EA Pharma.Eleview(R) is a sub
